{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:42:37Z","timestamp":1785894157585,"version":"3.56.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction and objectives<\/jats:title>\n                    <jats:p>Despite both hepatic arterial infusion chemotherapy (HAIC) and sorafenib being efficacious for hepatocellular carcinoma (HCC), choosing between them for Barcelona Clinic Liver Cancer (BCLC) stages B\/C patients remains controversial. This meta-analysis aims to compare their therapeutic outcomes and prognoses in such patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pubmed, EMBASE, and Web of Science databases were searched. The primary outcome of this meta-analysis is Overall Survival (OS), while secondary outcomes include Progression-Free Survival (PFS), tumor response rate, and the incidence of adverse events. The analysis has included a total of 18 studies, comprising 3008 patients in aggregate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis revealed a combined Hazard Ratio (HR) for OS of 0.57 (95% CI 0.38\u20130.86) and for PFS of 0.46 (95% CI 0.38\u20130.57). Subgroup analysis by different HAIC regimens: FOLFOX-based HAIC regimens 0.28\u00a0(95% CI: 0.16\u20130.50), FP regimen 0.68\u00a0(95% CI: 0.25\u20131.87), New-FP regimen 0.60 (95% CI: 0.47\u20130.77), cisplatin-based HAIC 0.63 (95% CI: 0.47\u20130.85). The pooled ORs were: Complete Response (CR) 3.88 (95% CI 1.56\u20139.65), Partial Response (PR)4.72(95% CI 2.44\u20139.13), Stable Disease (SD) 0.83 (95% CI 0.45\u20131.53), Progressive Disease (PD) 0.35 (95% CI0.25\u20130.48, Objective Response Rate (ORR) 5.32 (95% CI 2.54\u201311.13), Disease Control Rate (DCR) 2.03 (95% CI 1.05\u20133.92). For adverse events (AEs), the overall incidence Odds Ratios (OR) was 0.53 (95% CI 0.06\u20134.82) and for grade 3\u22124 events, 0.49 (95% CI 0.28\u20130.85).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Asian and African patients with BCLC stage B\/C hepatocellular carcinoma, HAIC\u2014particularly the FOLFOX regimen\u2014confers superior overall survival and oncologic outcomes compared to sorafenib, with higher response and disease control rates and reduced disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342495","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:28:36Z","timestamp":1771439316000},"page":"e0342495","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic arterial infusion chemotherapy (HAlC) versus sorafenib for hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) B\/C: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"21","author":[{"given":"Zhengqiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaotian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-7747","authenticated-orcid":true,"given":"Zhen","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"12","key":"pone.0342495.ref001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015","volume":"3","author":"Global Burden of Disease Liver Cancer Collaboration","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"pone.0342495.ref002","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"AG Singal","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0342495.ref003","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"10053","key":"pone.0342495.ref004","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Collaborators GBD 2015 Mortality and Causes of Death","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"pone.0342495.ref005","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.3390\/jcm11164874","article-title":"The combining of tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for advanced stage hepatocellular carcinoma","volume":"11","author":"S-W Lee","year":"2022","journal-title":"J Clin Med"},{"issue":"19","key":"pone.0342495.ref006","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"SM Wilhelm","year":"2004","journal-title":"Cancer Res"},{"issue":"24","key":"pone.0342495.ref007","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"L Liu","year":"2006","journal-title":"Cancer Res"},{"key":"pone.0342495.ref008","article-title":"Sorafenib in advanced hepatocellular carcinoma","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0342495.ref009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"A-L Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10126","key":"pone.0342495.ref010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"pone.0342495.ref011","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.7150\/thno.54822","article-title":"Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma","volume":"11","author":"F-H Kong","year":"2021","journal-title":"Theranostics"},{"issue":"10","key":"pone.0342495.ref012","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13411","article-title":"Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update","volume":"49","author":"N Kokudo","year":"2019","journal-title":"Hepatol Res"},{"key":"pone.0342495.ref013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000315244","article-title":"Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma","author":"K Ueshima","year":"2010","journal-title":"Oncology"},{"issue":"7","key":"pone.0342495.ref014","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.21873\/anticanres.13542","article-title":"Reduction of intrahepatic tumour by hepatic arterial infusion chemotherapy prolongs survival in hepatocellular carcinoma","volume":"39","author":"PS Sung","year":"2019","journal-title":"Anticancer Res"},{"issue":"10","key":"pone.0342495.ref015","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/jgh.14152","article-title":"Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status","volume":"33","author":"K Kodama","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"17","key":"pone.0342495.ref016","article-title":"Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: a STROBE-compliant article","volume":"97","author":"MK Kang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"pone.0342495.ref017","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1743-7563.2012.01543.x","article-title":"The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma","volume":"8","author":"SW Jeong","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"pone.0342495.ref018","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/j.1440-1746.2011.06751.x","article-title":"Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments","volume":"26","author":"HY Kim","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"pone.0342495.ref019","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3892\/etm.2011.237","article-title":"Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: a comparative study","volume":"2","author":"Y Hiramine","year":"2011","journal-title":"Exp Ther Med"},{"issue":"9","key":"pone.0342495.ref020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jjco\/hyz069","article-title":"Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"49","author":"B Zhuang","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"pone.0342495.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"A Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"pone.0342495.ref022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"pone.0342495.ref023","author":"National Cancer Institute","year":"2010"},{"key":"pone.0342495.ref024","author":"National Cancer Institute","year":"2010"},{"key":"pone.0342495.ref025","author":"National Cancer Institute","year":"2017"},{"issue":"3","key":"pone.0342495.ref026","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"C Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"issue":"2","key":"pone.0342495.ref027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3350\/cmh.2016.0071","article-title":"A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function","volume":"23","author":"H Yang","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"pone.0342495.ref028","doi-asserted-by":"crossref","first-page":"631","DOI":"10.21037\/hbsn.2020.03.14","article-title":"Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice","volume":"10","author":"S Li","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"19","key":"pone.0342495.ref029","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.3390\/cancers14194873","article-title":"The Clinical impact of hepatic arterial infusion chemotherapy new-FP for hepatocellular carcinoma with preserved liver function","volume":"14","author":"H Iwamoto","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0342495.ref030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/cancers13040646","article-title":"Survival benefit of hepatic arterial infusion chemotherapy over sorafenib in the treatment of locally progressed hepatocellular carcinoma","volume":"13","author":"H Iwamoto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"pone.0342495.ref031","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221117389","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus sorafenib for hepatocellular carcinoma refractory to transarterial chemoembolization: retrospective subgroup analysis of 2 prospective trials","volume":"21","author":"Y Huang","year":"2022","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"pone.0342495.ref032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"N Lyu","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0342495.ref033","author":"Y Zaizen","year":"2021"},{"issue":"3","key":"pone.0342495.ref034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1751-2980.12221","article-title":"Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting","volume":"16","author":"M Kondo","year":"2015","journal-title":"J Dig Dis"},{"issue":"9","key":"pone.0342495.ref035","article-title":"Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study","volume":"76","author":"AHK Abdelmaksoud","year":"2021","journal-title":"Clin Radiol"},{"issue":"7","key":"pone.0342495.ref036","first-page":"3523","article-title":"Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization","volume":"36","author":"M Hatooka","year":"2016","journal-title":"Anticancer Res"},{"issue":"9","key":"pone.0342495.ref037","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/1751-2980.12267","article-title":"Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma","volume":"16","author":"T Kawaoka","year":"2015","journal-title":"J Dig Dis"},{"issue":"5","key":"pone.0342495.ref038","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)","volume":"40","author":"N Lyu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0342495.ref039","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00535-014-0978-3","article-title":"A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"50","author":"DS Song","year":"2015","journal-title":"J Gastroenterol"},{"key":"pone.0342495.ref040","unstructured":"Shiozawa K, Watanabe M, Ikehara T, Kogame M, Matsui T, Okano N. Comparison of sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a propensity score matching study. 2014."},{"issue":"2","key":"pone.0342495.ref041","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5009\/gnl19367","article-title":"Comparison of sorafenib versus hepatic arterial infusion chemotherapy-based treatment for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"15","author":"YE Ahn","year":"2021","journal-title":"Gut Liver"},{"issue":"5","key":"pone.0342495.ref042","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1159\/000508724","article-title":"Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma","volume":"9","author":"K Ueshima","year":"2020","journal-title":"Liver Cancer"},{"issue":"3","key":"pone.0342495.ref043","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","article-title":"Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"82","author":"JH Choi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"pone.0342495.ref044","article-title":"Contributions to liver blood flow of the portal vein and hepatic artery","volume":"118","author":"M Ginsberg","year":"1952","journal-title":"J Physiol"},{"issue":"5","key":"pone.0342495.ref045","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"C Breedis","year":"1954","journal-title":"Am J Pathol"},{"issue":"1","key":"pone.0342495.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","article-title":"Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma","volume":"367","author":"J Chen","year":"2015","journal-title":"Cancer Lett"},{"key":"pone.0342495.ref047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"M Levrero","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0342495.ref048","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gutjnl-2013-306228","article-title":"Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas","volume":"64","author":"G Amaddeo","year":"2015","journal-title":"Gut"},{"issue":"7","key":"pone.0342495.ref049","first-page":"754","article-title":"Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition)","volume":"20","author":"Chinese Society of Liver Cancer","year":"2021","journal-title":"Chin J Dig Surg"},{"issue":"5","key":"pone.0342495.ref050","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"L N","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"pone.0342495.ref051","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0342495.ref052","first-page":"893","article-title":"Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)","volume":"40","author":"National Health Commission of the People\u2019s Republic of China","year":"2024","journal-title":"J Clin Hepatol"},{"issue":"5","key":"pone.0342495.ref053","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)","volume":"53","author":"The Committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma","year":"2023","journal-title":"Hepatol Res"},{"key":"pone.0342495.ref054","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","article-title":"Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial","volume":"174","author":"Z Lai","year":"2022","journal-title":"Eur J Cancer"},{"key":"pone.0342495.ref055","doi-asserted-by":"crossref","first-page":"1127349","DOI":"10.3389\/fimmu.2023.1127349","article-title":"Hepatic arterial infusion chemotherapy combined with anti-PD-1\/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study","volume":"14","author":"W Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0342495.ref056","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.62347\/YMXR8481","article-title":"FOLFOX-HAIC combined with PD-1 inhibitor immunotherapy significantly improves survival in patients with advanced hepatocellular carcinoma","volume":"17","author":"J Xu","year":"2025","journal-title":"Am J Transl Res"},{"key":"pone.0342495.ref057","article-title":"Hepatic arterial infusion chemotherapy combined lenvatinib and PD-1 inhibitor showed improved survival for infiltrative hepatocellular carcinoma: a multicenter cohort study","volume":"11","author":"L R","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"issue":"11","key":"pone.0342495.ref058","first-page":"5455","article-title":"Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas","volume":"13","author":"Z Lin","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"2","key":"pone.0342495.ref059","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1743-7563.2010.01287.x","article-title":"Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma","volume":"6","author":"Y-Y Shao","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"pone.0342495.ref060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000367746","article-title":"Current status of hepatic arterial infusion chemotherapy","volume":"4","author":"S Obi","year":"2015","journal-title":"Liver Cancer"},{"issue":"8","key":"pone.0342495.ref061","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jgh.15010","article-title":"Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis","volume":"35","author":"M Liu","year":"2020","journal-title":"J Gastroenterol Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:28:45Z","timestamp":1771439325000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342495"}},"subtitle":[],"editor":[{"given":"Do Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342495","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}